MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:40Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Antidiarrheals]]
			[[Category:Opioid receptor agonists]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #276

2026-05-23T04:08:52Z

parser-claude batch MedTemplate pre-fill, Top 300 #276

New page

{{MedTemplate
| generic = Loperamide
| brand = Imodium, Imodium A-D
| structure =
| classes = [[:Category:Antidiarrheals|Antidiarrheal]], [[:Category:Opioid_receptor_agonists|Peripheral opioid receptor agonist (μ-selective, gut-restricted)]]
| uses = <vote slug="acute-diarrhea-use">Acute non-infectious diarrhea</vote>, <vote slug="ibs-d-use">IBS with predominant diarrhea</vote>, <vote slug="chronic-diarrhea-use">Chronic diarrhea (selected; cancer, post-cholecystectomy, ostomy)</vote>
| starting_dose = 4 mg PO initially, then 2 mg after each loose stool, '''not to exceed 16 mg/d''' (8 mg OTC); chronic-use lower
| preparations = 2 mg capsules and tablets; 1 mg/5 mL oral solution; combined with simethicone (Imodium Multi-Symptom)
| fda_max = 16 mg/d (8 mg/d OTC)
| pill_id =
| routes = Oral
| onset = 30-60 minutes
| duration = 8-12 hours
| halflife = ~9-14 hours<ref name="imodium-label">FDA Prescribing Information, Imodium (loperamide HCl), Janssen, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017694s056lbl.pdf</ref>
| bioavailability = ~0.3% (oral; extensive first-pass via CYP3A4 and P-glycoprotein-mediated efflux at the intestinal and blood-brain barriers limit systemic and CNS exposure at therapeutic doses)<ref name="imodium-label" />
| pregnancy = Generally considered acceptable when needed.{{citation needed}}
| legal = OTC in US
| mechanism = <vote slug="loperamide-mech-claim">Loperamide is a peripherally-acting μ-opioid receptor agonist that slows gut motility and prolongs transit; the absence of CNS analgesia, euphoria, and dependence at therapeutic doses reflects active P-glycoprotein efflux at the blood-brain barrier that keeps CNS concentrations subtherapeutic.</vote> '''Cardiotoxicity at high doses''' (FDA 2016 advisory): supratherapeutic use (sometimes for opioid-substitute euphoria or unintentional megadosing) saturates P-gp, allows systemic accumulation, and produces dose-dependent QT prolongation, torsades, and ventricular arrhythmia. Interactions with CYP3A4/P-gp inhibitors can elevate systemic exposure at standard doses<ref name="imodium-label" />.
}}

== References ==
<references />

Loperamide - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #276